Business
Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board
Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board\n\n\n\n\n\nAmarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board\nPR Newswire\nSAN FRANCISCO, March 4, 2016\n\n\n\nSAN FRANCISCO, March 4, 2016 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has appointed Brian E. Harvey, MD PhD to its strategic advisory board. Dr. Harvey will assist the company's management team in developing and executing its strategy to accelerate FDA regulatory approval for its orphan drug portfolio of products.\n\n\"I am excited to help Amarantus accelerate regulatory interactions with the FDA for its diverse orphan drug portfolio of products,\" said Dr. Harvey. \"ESS and Eltoprazine are moving into mid and late stage development across several niche indications where the standard of care has not seen any significant innovation in over 50 years. ESS is a product candidate that demands careful, focused clinical and regulatory execution in order to bring this life-saving treatment to market as expeditiously as possible. With respect to Eltoprazine and its recent Orphan designation, Amarantus has an opportunity to redefine the regulatory pathway to approval for Eltoprazine with its recent orphan drug designation, and we intend to engage the regulatory authorities in discussions as it relates to this pathway forward.\"\n\n\"We are very pleased to have attracted Dr. Harvey to our Strategic Advisory Committee to further enhance our already strong regulatory science infrastructure as we prepare to engage the FDA in discussions regarding the pathway forward for the late-stage development of ESS and Eltoprazine,\" said Gerald E. Commissiong, President & CEO. \"As we are rapidly approaching the initiation of the ESS clinical development program with the US Army for the treatment of severe burns, we foresee the burn community strongly advocating for an accelerated approval process to bring this life-saving treatment to market. We want to ensure that we have the experience and infrastructure at the ready to manage various potential scenarios as it relates to ESS.\"\n\nAbout Dr. Harvey's Experience \n\nDr. Harvey recently served as Vice President of U.S Regula...